Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the SARS-CoV-2 Omicron variant.

Related Keywords

United States , ,Coronavirus Disease Covid 19 ,Prophylaxis ,Cars ,Ars Cov 2 ,Antibodies ,Ntibody ,Coronavirus ,Covid 19 ,Efficacy ,Mmunoglobulin ,Mmunology ,N Vivo ,Manufacturing ,Monoclonal Antibody ,Ortality ,Nanobodies ,Micron ,Pandemic ,Protein ,Eceptor ,Espiratory ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Spike Protein ,Yndrome ,Ransgenic ,Least ,